IP Library Granted Patent US 12,392,787
Granted Patent B2
US 12,392,787 · App. 16/250,850 · Granted Aug 19, 2025

Method for quantifying the amount of cholesterol in high-density lipoprotein 3

Inventors: Maiko Higuchi (Gosen, JP); Yasuki Itoh (Gosen, JP)
Assignee: DENKA COMPANY LIMITED
G01N33/92C12Q1/44C12Q1/60G01N2333/918G01N2405/04G01N2405/08G01N2800/323
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,392,787
App. No.
16/250,850
Granted
Aug 19, 2025
Kind
B2
Abstract

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and/or sphingomyelinase is/are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

Claims (17)

1. A method of quantifying cholesterol in high-density lipoprotein 3 (HDL3), said method comprising:

reacting a test sample with phospholipase and/or sphingomyelinase;

simultaneously or subsequently reacting the test sample with a first surfactant that reacts with lipoproteins other than HDL3 to eliminate or protect cholesterol and any esters thereof; and

subsequently reacting the test sample with a second surfactant that reacts with HDL3 to quantify remaining cholesterol in the test sample.

2. The method according to claim 1 , wherein said phospholipase is phospholipase C and/or phospholipase D.

3. The method according to claim 1 , wherein said second surfactant comprises polyoxyethylene distyrene-modified phenyl ether, which is a nonionic surfactant.

4. The method according to claim 1 , wherein said first surfactant is selected from the group consisting of polyoxyethylene-polyoxypropylene condensates, polyoxyethylenestearylamine, amide ether sulfate, and a combination thereof.

5. The method according to claim 1 , wherein said first surfactant comprises at least one amphoteric surfactant selected from the group consisting of coconut oil fatty acid-amidopropyldimethyl-aminoacetic acid betaine, alkyl dimethyl-aminoacetic acid betaine, and lauryl betaine.

6. The method according to claim 1 , wherein said first surfactant comprises lauryl trimethyl ammonium chloride, which is a cationic surfactant.

7. The method according to claim 1 , wherein said second surfactant comprises at least one nonionic surfactant selected from the group consisting of polyoxyethylene distyrene-modified phenyl ether, polyoxyethylene lauryl ether, and p-isooctyl polyoxyethylene phenol formaldehyde polymers.

8. The method according to claim 1 , wherein said second surfactant comprises a combination of: (1) lauryl dimethyl-aminoacetic acid betaine, which is an amphoteric surfactant, and (2) polyoxyethylene lauryl ether, which is a nonionic surfactant.

9. The method according to claim 1 , wherein said second surfactant comprises a fatty acid series phosphoric acid ester, which is an anionic surfactant.

10. The method according to claim 1 , wherein said second surfactant comprises at least one nonionic surfactant having a hydrophilic-lipophilic balance (HLB) of 11 to 14, selected from the group consisting of polyoxyethylene distyrene-modified phenyl ether, polyoxyethylene tribenzyl phenyl ether, polyoxyalkylene alkyl ether, polyoxyethylene polycyclic phenyl ether, and polyoxyethylene cumyl phenyl ether.

11. The method according to claim 1 , wherein said second surfactant comprises at least one imidazoline-type amphoteric surfactant.

12. The method according to claim 1 , wherein said second surfactant comprises at least one nonionic surfactant selected from the group consisting of polyoxyethylene lauryl ether, polyoxyethylene alkyl ether, and polyoxyethylene alkyl phenyl ether.

13. The method according to claim 1 , wherein said second surfactant comprises: (1) lauryl alcohol alkoxylate, which is a nonionic surfactant; and/or (2) sodium polyoxyethylene-alkyl phenyl ether sulfate, which is an anionic surfactant.

14. The method according to claim 1 , wherein said first surfactant is a polyoxyethylene-polyoxypropylene condensate, and said second surfactant is a polyoxyethylene polycyclic phenyl ether.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBERS 10007286 AND 10415007 PREVIOUSLY RECORDED AT REEL: 054513 FRAME: 0142. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Dec 14, 2020
From: DENKA SEIKEN CO., LTD.
To: DENKA COMPANY LIMITED
Reel/Frame 055437/0045 →
MERGER Recorded Nov 24, 2020
From: DENKA SEIKEN CO., LTD.
To: DENKA COMPANY LIMITED
Reel/Frame 054513/0142 →
Priority Claims (1)
JP 2010-166317 · Jul 23, 2010 · national
Continuity (2)
Continuation 13811562
Related Publication 20190154711A1 · May 23, 2019
References Cited (23)
US 7851174B2 · Katayama et al. · 2010 [cited by applicant]
US 20050287619A1 · Katayama et al. · 2005 [cited by applicant]
US 20060014207A1 · Yamamoto · 2006 [cited by examiner]
US 20090181413A1 · Itoh · 2009 [cited by examiner]
US 20090188812A1 · Broughall et al. · 2009 [cited by applicant]
US 20100255516A1 · Itoh · 2010 [cited by examiner]
JP 2001346598A · 2001 [cited by applicant]
JP 2009207463A · 2009 [cited by applicant]
WO WO2005100591A1 · 2005 [cited by applicant]
WO WO2007132226A1 · 2007 [cited by applicant]
WO WO2009048143 · 2009 [cited by examiner]
WO WO2009048143A1 · 2009 [cited by applicant]
English translation of Koji et al., JP-2001-346598. [cited by examiner]
Ahmadraji, T. and A. J. Killard, “The evolution of selective analyses of HDL and LDL cholesterol in clinical and point of care testing,” Analytical Methods (2013), vol. 5, pp. 3612-3625. [cited by applicant]
Chollet et al., “Phospholipase A2-treated human high-density lipoprotein and cholesterol movements: exchange processes and lecithin: cholesterol acyltransferase reactivity,” Biochimica et Biophysica Acta (1986), vol. 87… [cited by applicant]
Extended European Search Report issued Dec. 17, 2013, in European Patent Application No. 11809724.5. [cited by applicant]
Ito et al., “Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol,” Clinical Chimica Acta (2014) vol. 427, pp. 86-93. [cited by applicant]
Lottin et al., “Differential effects of glycero- and sphingo-phospholipolysis on human high-density lipoprotein fludity,” Biochimica et Biophysica Acta (1996), vol. 1301, pp. 127-132. [cited by applicant]
Miida et al., “Recent advances in the research of HDL subfraction,” Rinsho Byori (2010), vol. 58, pp. 606-612. [cited by applicant]
Okada et al. “Direct Measurement of HDL Cholesterol: Method Eliminating Apolipoprotein E-Rich Properties,” Journal of Clinical Laboratory Analysis (2001), vol. 15, pp. 223-229. [cited by applicant]
Emulgen, Emulgen Product Sheet, 2014. [cited by applicant]
Ito et al., “Development of a Homogenous Assay for Measurment of Small Dense LDL Cholesterol”, Clinical Chemistry 57:1, pp. 57-65, 2011. [cited by applicant]
Koji, Translation of JP-2001-346598, 2001. [cited by applicant]